Clinical and Laboratory Factors Associated with Symptom Development in Asymptomatic COVID-19 Patients at the Time of Diagnosis

Hong Sang Oh, Joon Ho Kim, Myoung Lyeol Woo, Ji-Yeon Kim, Chul Hee Park, Hyejin Won, Seungkwan Lim, Hyeonju Jeong, Sin Young Ham, Eun Jin Kim, Seungsuee Sheen, Yu Min Kang, Doran Yoon, Seung Youp Lee, and Kyoung-Ho Song

Department of Internal Medicine, Armed Forces Capital Hospital, Seongnam, Korea
Department of Surgery, Gyeonggi Provincial Medical Center, Uijeongbu Hospital, Uijeongbu, Korea
Department of Internal Medicine, Gyeonggi Provincial Medical Center, Uijeongbu Hospital, Uijeongbu, Korea
Division of Infectious Disease, Department of Medicine, Seongnam Citizens Medical Center, Seongnam, Korea
Department of Internal Medicine, Gyeonggi Provincial Medical Center, Icheon Hospital, Icheon, Korea
Department of Internal Medicine, Gyeonggi Provincial Medical Center, Pocheon Hospital, Pocheon, Korea
Department of Internal Medicine, Gyeonggi Provincial Medical Center, Ansan Hospital, Ansan, Korea
Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University, College of Medicine, Seongnam, Korea
Department of Infectious Disease, Ajou University, School of Medicine, Suwon, Korea
Department of Pulmonary Critical Care Medicine, Ajou University, School of Medicine, Suwon, Korea
Division of Infectious Disease, Department of Internal Medicine, Myongji Hospital, Goyang, Korea
Department of Emergency Medicine, Gyeonggi Provincial Medical Center, Ansan Hospital, Anseong, Korea

ABSTRACT

In preparation for the surge of coronavirus disease 2019 (COVID-19), it is crucial to allocate medical resources efficiently for distinguishing people who remain asymptomatic until the end of the disease. Between January 27, 2020, and April 21, 2020, 517 COVID-19 cases from 13 healthcare facilities in Gyeonggi province, Korea, were identified out of which the epidemiologic and clinical information of 66 asymptomatic patients at the time of diagnosis were analyzed retrospectively. An exposure-diagnosis interval within 7 days and abnormal aspartate aminotransferase levels were identified as characteristic symptom development in asymptomatic COVID-19 patients. If asymptomatic patients without these characteristics at the time of diagnosis could be differentiated early, more medical resources could be secured for mild or moderate cases in this COVID-19 surge.

Keywords: COVID-19; SARS-CoV-2; Asymptomatic; Symptom development; Medical resource allocation

Coronavirus disease 2019 (COVID-19) originated in China in 2019 and soon became a pandemic [1]. However, newly developed COVID-19 vaccines have been distributed globally in early 2021 to manage the ongoing pandemic [2]. Asymptomatic patients were rapidly diagnosed in Korea through aggressive tracing and testing during the early phase of this pandemic [3]. Early identification of asymptomatic patients from mild or moderate cases...
is important while preparing to control this pandemic surge for efficient management of medical resources. People who remain asymptomatic until the end of the disease, if predicted in advance will help them isolate through home management [4] and not in a healthcare facility. For this reason, it is imperative to understand the clinical and laboratory factors associated with symptom development in asymptomatic patients at the time of diagnosis.

Between January 27, 2020, and April 21, 2020, 517 COVID-19 cases, from 13 healthcare facilities in Gyeonggi province, Korea was identified out of which 72 (13.9%) was found to be asymptomatic at the time of diagnosis. All confirmed patients were admitted and isolated during the early phase of the pandemic. Clinical information through medical records, including vital signs, laboratory results, and daily attending doctor and nurse progression notes using standardized uniform case record form, was retrospectively reviewed by the researchers thoroughly at each facility. This study was approved by the Institutional Ethics Review Board of Seoul National University Bundang Hospital (No. B-2005-612-108). The median age of 72 asymptomatic cases was 50.5 years [interquartile range (IQR), 28 - 61 years]. Six cases were under the age of 18 and hence, were excluded from this study. Among the 66 patients, 38 (57.6%) were over 50 years old and 24 (46.4%) had one or more underlying diseases. Exposure dates were confirmed in 39 (59.1%) cases and 33 (50.0%) asymptomatic patients who developed symptoms during hospitalization. The median duration of isolation was 10 days (IQR, 6 - 16 days).

Patients who were asymptomatic till the end of the disease were defined as ‘asymptomatic group’ and patients who developed symptoms during the illness were defined as ‘pre-symptomatic group’. Out of the patients whose exposure date was confirmed, 17 (51.5%) were asymptomatic till the date of discharge, while 22 (66.6%) developed clinical symptoms during hospitalization. The median age of the asymptomatic and the pre-symptomatic groups was 50 years (IQR, 28.5 - 59.5) and 54 years (IQR, 39.5 - 64.5), respectively. The total number of male patients in the asymptomatic and the pre-symptomatic groups were 15 (45.5%) and 9 (27.3%). The laboratory test results revealed a significantly decreased initial hemoglobin level (g/dL) (10.0 ± 1.2 vs. 9.2 ± 0.7) and not in a healthcare facility. For this reason, it is imperative to understand the clinical and laboratory factors associated with symptom development in asymptomatic patients at the time of diagnosis.

| Variables       | Total (n = 66) | Asymptomatic group (n = 33) | Pre-symptomatic group (n = 33) | P-value |
|-----------------|---------------|----------------------------|-------------------------------|---------|
| Age, median (IQR), years | 51.5 (30.5, 61.2) | 50 (28.5, 59.5) | 54 (39.5, 64.5) | 0.325 |
| Age-group, years |               |                           |                               |         |
| 18 - 49         | 28 (42.4)     | 16 (48.5)                 | 12 (36.4)                     | 0.455   |
| Over 50         | 39 (57.6)     | 17 (51.5)                 | 21 (63.6)                     |         |
| Male, n (%)     | 24 (36.4)     | 15 (45.5)                 | 9 (27.3)                      | 0.125   |

(continued to the next page)
Variables such as AST and exposure-diagnosis interval displayed \( P < 0.1 \) in the univariate analysis. Other important risk factors including age, neutrophilia, lymphopenia, hypertension, diabetes mellitus, and smoking were included in the multivariate Cox regression model (Table 2) [5, 6].
The results showed that exposure-diagnosis interval within 7 days [hazard ratio (HR), 4.334; 95% confidence interval (CI), 1.453 - 12.931; \( P = 0.009 \)] and AST over 50 IU/dL (HR, 16.804; 95% CI, 2.667 - 105.900; \( P = 0.003 \)) were clinical and laboratory factors associated with symptom development in the asymptomatic group at the time of diagnosis. It could be assumed that no clinical symptoms developed 7 days after exposure. This exceeded the known serial interval and median incubation period [7]. In other words, the median of 13.5 days after exposure in the asymptomatic group was nearly up to maximum incubation period. We assumed that the incubation period would be extended due to low inoculum exposure in asymptomatic groups, which were all contact traced and diagnosed under self-isolation after close-contact or overseas arrival at the early phase of pandemic, rather than just delayed diagnosed with barely recognizable symptoms. Furthermore, a normal AST level at the time of diagnosis could predict an asymptomatic state until discharge. Previous studies have reported elevated levels of hepatic enzymes in severe COVID-19 infections [8], indicating that the disease is a systemic inflammatory response and not limited to the lungs. Therefore, it might be possible that the host inflammatory reaction did not occur excessively in asymptomatic patients [9].
This study has several limitations. First, a thorough epidemiological investigation capability must be supported to determine the prognosis for the disease by exposure date. Therefore, it might be difficult to apply this result to other countries where epidemiological investigation capabilities are insufficient. Second, since this study took place in the early phase of the pandemic, the number of asymptomatic patients was inadequate and different variants of the virus were not considered. A systematic observational study involving a large number of asymptomatic patients amid the Delta variant surge is needed in the future. Third, all clinical information and laboratory results were obtained at the time of hospital admission; thus, the gap between exposure and diagnosis might have varied individually. Fourth, most of the asymptomatic patients or those with mild symptoms were recently admitted to community treatment centers that were unable to host blood tests; hence, an increase in unknown exposure would be a drawback to clinical application.

This study suggested that COVID-19 patients with exposure-diagnosis intervals over 7 days and normal AST levels on admission could remain asymptomatic through the end of the disease. During the disease surge, if people with these characteristics would be treated through home management or community treatment centers and not in healthcare facilities, more medical resources could be reserved for patients with mild or moderate symptoms.

**ACKNOWLEDGEMENTS**

We express our gratitude to Won Seok Choi (Korea University Ansan Hospital), Jongtak Jung, Heeyoung Lee, Eu Suk Kim, and Hong Bin Kim (Seoul National University Bundang Hospital) for their efforts to patient recruitment and advise for manuscript preparation.
REFERENCES

1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W; China novel coronavirus investigating and research team. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020;382:727-33.

2. Hodgson SH, Mansatta K, Mallett G, Harris V, Emary KRW, Pollard AJ. What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2. Lancet Infect Dis 2021;21:e26-35.

3. Kang J, Jang YH, Kim J, Han SH, Lee KR, Kim M, Eom JS. South Korea’s responses to stop the COVID-19 pandemic. Am J Infect Control 2020;48:1080-6.

4. Lee Y, Han JO, Lee H, Lim S. The development and operation of a home management system during the COVID-19 pandemic: experience of the local government Gyeonggi-do in Korea. J Korean Med Sci 2021;36:e134.

5. Izcovich A, Ragusa MA, Tortosa F, Lavena Marzio MA, Agnoletti C, Bengolea A, Ceirano A, Espinosa F, Saavedra E, Sanguine V, Tassara A, Ced C, Catalano HN, Agurwal A, Foroutan F, Rada G. Prognostic factors for severity and mortality in patients infected with COVID-19: A systematic review. PLoS One 2020;15:e0241955.

6. Wynants L, Van Calster B, Collins GS, Riley RD, Heinz G, Schuit E, Bonten MMJ, Dahly DL, Damen JAA, Debray TPA, de Jong VMT, De Vos M, Dhiman P, Haller MC, Harhay MO, Henckaerts L, Heus P, Kammer M, Kreuzberger N, Lohmann A, Luijken K, Ma J, Martin GP, McLearnon DJ, Andeur Navarro CL, Reitsma JB, Sergeant JC, Shi C, Skoetz N, Smits LJ, Snell KIE, Sperrin M, Spijker R, Steyerberg EW, Takada T, Tzoulaki I, van Kuijk SMJ, van Bussel B, van der Horst ICC, van Roijen FS, Verhake JY, Wallisch C, Wilkinson J, Wooff R, Hooft L, Moons KGM, van Smeden M. Prediction models for diagnosis and prognosis of covid-19: systematic review and critical appraisal. BMJ 2020;369:m1328.

7. Xie Y, Wang Z, Liao H, Marley G, Wu D, Tang W. Epidemiologic, clinical, and laboratory findings of the COVID-19 in the current pandemic: systematic review and meta-analysis. BMC Infect Dis 2020;20:640.

8. Wang Q, Zhao H, Liu LG, Wang YB, Zhang T, Li MH, Xu YL, Gao GI, Xiong HF, Fan Y, Cao Y, Ding R, Wang JF, Cheng C, Xie W. Pattern of liver injury in adult patients with COVID-19: a retrospective analysis of 105 patients. Mil Med Res 2020;7:28.

9. Hao SR, Zhang SY, Jin X, Ye CY, Cai H, Zhang XL, Hu JH, Zheng L, Zhang YM, Jia HY, Yu GD, Wang XY, Gu IQ, Lu YF, Yu XP, Yu L, Xiang DR, Ye CY, Jin CL, Qiu YQ, Li LJ, Sheng JF, Liang TB, Yang YD. Liver enzyme elevation in coronavirus disease 2019: a multicenter, retrospective, cross-sectional study. Am J Gastroenterol 2020;115:1075-83.

10. Kang E, Lee SY, Jung H, Kim MS, Cho B, Kim YS. Operating protocols of a community treatment center for isolation of patients with coronavirus disease, South Korea. Emerg Infect Dis 2020;26:2329-37.